Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

Joe Y. Chang; Vivek Verma; James Welsh; Silvia C. Formenti

doi:10.1016/S1470-2045(22)00134-6

Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

Joe Y. Chang, Vivek Verma, James Welsh, Silvia C. Formenti

Radiation Oncology

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	e156
Journal	The lancet oncology
Volume	23
Issue number	4
DOIs	https://doi.org/10.1016/S1470-2045(22)00134-6
State	Published - Apr 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(22)00134-6

Cite this

@article{a62eb416fe0a483b9eef86547ae3c569,

title = "Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC",

author = "Chang, {Joe Y.} and Vivek Verma and James Welsh and Formenti, {Silvia C.}",

note = "Funding Information: JYC reports a research grant from Bristol-Myers Squibb, consulting fees from Legion Healthcare Partners, and being a shareholder for Global Oncology One. JWW reports research support from GlaxoSmithKline, Bristol-Myers Squibb, Merck, Nanobiotix, RefleXion, Alkermes, Artidis, Mavu Pharma, Takeda, Varian, and Checkmate Pharmaceuticals. JWW serves or has served on the scientific advisory board for Legion Healthcare Partners, RefleXion Medical, MolecularMatch, Merck, AstraZeneca, Aileron Therapeutics, OncoResponse, Checkmate Pharmaceuticals, Mavu Pharma, Alpine Immune Sciences, Ventana Medical Systems, Nanobiotix, China Medical Tribune, GI Innovation, Genentech, and Nanorobotix. JWW serves as consultant for Lifescience Dynamics Limited. JWW has or had speaking engagements for Ventana Medical Systems, US Oncology, Alkermes, and Boehringer Ingelheim. JWW holds or held stock or ownership in Alpine Immune Sciences, Checkmate Pharmaceuticals, Healios, Mavu Pharma, Legion Healthcare Partners, MolecularMatch, Nanorobotix, OncoResponse, and RefleXion. JWW has accepted honoraria in the form of travel costs from Nanobiotix, RefleXion, Varian, Shandong University, The Korea Society of Radiology, Aileron Therapeutics, and Ventana. JWW has the following patents: MP470 (amuvatinib), MRX34 regulation of PDL1, and XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopalTM. SCF reports research grants from Merck, Varian, Bristol-Myers Squibb, Regeneron, Eisai, and Eli Lilly; consulting fees from Accuray, Boehringer Ingelheim, Roche, Genentech, AstraZeneca, and Viewray; support for attending meetings or travel from Bayer, Bristol-Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, Eisai, AstraZeneca, Medlmmune, Merck US, EMDSerono/Merck, and Accuray. VV declares no competing interests.",

year = "2022",

month = apr,

doi = "10.1016/S1470-2045(22)00134-6",

language = "English (US)",

volume = "23",

pages = "e156",

journal = "The lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

AU - Chang, Joe Y.

AU - Verma, Vivek

AU - Welsh, James

AU - Formenti, Silvia C.

N1 - Funding Information: JYC reports a research grant from Bristol-Myers Squibb, consulting fees from Legion Healthcare Partners, and being a shareholder for Global Oncology One. JWW reports research support from GlaxoSmithKline, Bristol-Myers Squibb, Merck, Nanobiotix, RefleXion, Alkermes, Artidis, Mavu Pharma, Takeda, Varian, and Checkmate Pharmaceuticals. JWW serves or has served on the scientific advisory board for Legion Healthcare Partners, RefleXion Medical, MolecularMatch, Merck, AstraZeneca, Aileron Therapeutics, OncoResponse, Checkmate Pharmaceuticals, Mavu Pharma, Alpine Immune Sciences, Ventana Medical Systems, Nanobiotix, China Medical Tribune, GI Innovation, Genentech, and Nanorobotix. JWW serves as consultant for Lifescience Dynamics Limited. JWW has or had speaking engagements for Ventana Medical Systems, US Oncology, Alkermes, and Boehringer Ingelheim. JWW holds or held stock or ownership in Alpine Immune Sciences, Checkmate Pharmaceuticals, Healios, Mavu Pharma, Legion Healthcare Partners, MolecularMatch, Nanorobotix, OncoResponse, and RefleXion. JWW has accepted honoraria in the form of travel costs from Nanobiotix, RefleXion, Varian, Shandong University, The Korea Society of Radiology, Aileron Therapeutics, and Ventana. JWW has the following patents: MP470 (amuvatinib), MRX34 regulation of PDL1, and XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopalTM. SCF reports research grants from Merck, Varian, Bristol-Myers Squibb, Regeneron, Eisai, and Eli Lilly; consulting fees from Accuray, Boehringer Ingelheim, Roche, Genentech, AstraZeneca, and Viewray; support for attending meetings or travel from Bayer, Bristol-Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, Eisai, AstraZeneca, Medlmmune, Merck US, EMDSerono/Merck, and Accuray. VV declares no competing interests.

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85127071552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127071552&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(22)00134-6

DO - 10.1016/S1470-2045(22)00134-6

M3 - Letter

C2 - 35358456

AN - SCOPUS:85127071552

SN - 1470-2045

VL - 23

SP - e156

JO - The lancet oncology

JF - The lancet oncology

IS - 4

ER -

Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this